Short-Read Sequencing

Short-Read Sequencing

Global Short-Read Sequencing Market to Reach US$38.5 Billion by 2030

The global market for Short-Read Sequencing estimated at US$19.8 Billion in the year 2023, is expected to reach US$38.5 Billion by 2030, growing at a CAGR of 9.9% over the analysis period 2023-2030. Next-Generation Sequencing Technology, one of the segments analyzed in the report, is expected to record a 9.6% CAGR and reach US$25.0 Billion by the end of the analysis period. Growth in the Sanger Sequencing Technology segment is estimated at 10.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.5 Billion While China is Forecast to Grow at 9.2% CAGR

The Short-Read Sequencing market in the U.S. is estimated at US$5.5 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$5.8 Billion by the year 2030 trailing a CAGR of 9.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.1% and 8.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.0% CAGR.

Global Short-Read Sequencing Market - Key Trends and Drivers Summarized

How Is Short-Read Sequencing Transforming Genomics?

Short-read sequencing is a next-generation sequencing (NGS) technology that reads short fragments of DNA, typically between 100 and 300 base pairs. It is widely used in genomics for applications such as whole-genome sequencing, targeted sequencing, and RNA sequencing. Renowned for its high accuracy, scalability, and cost-effectiveness, short-read sequencing plays a critical role in research areas like cancer genomics, personalized medicine, and microbiome studies. As advancements in bioinformatics enhance data analysis capabilities, short-read sequencing continues to be a powerful tool for understanding genetic variation, disease mechanisms, and population genetics.

What Are the Key Segments in the Short-Read Sequencing Market?

Key technologies include Illumina sequencing and Ion Torrent sequencing, with Illumina sequencing holding a major share due to its high accuracy, extensive throughput, and broad application range. Applications span across oncology, infectious disease research, genetic testing, and agricultural genomics, with oncology accounting for a significant market share as cancer research and diagnostics rely heavily on DNA sequencing for precision medicine. End-users include research institutions, clinical laboratories, pharmaceutical companies, and academic centers, with research institutions leading the market due to their focus on genomics studies and disease research.

How Is Short-Read Sequencing Being Used Across Research and Clinical Applications?

In oncology, short-read sequencing is used for detecting somatic mutations, copy number variations, and gene fusions, facilitating personalized cancer treatment strategies. Infectious disease research leverages short-read sequencing to identify pathogens, track outbreaks, and study antimicrobial resistance, supporting public health initiatives. Genetic testing applications utilize short-read sequencing to identify genetic disorders, aiding in diagnostics and reproductive health management. In agriculture, short-read sequencing is applied in crop genomics and breeding programs to improve yield, resistance, and nutritional value. Additionally, the integration of bioinformatics and cloud computing has enhanced the analysis of large-scale sequencing data, enabling more accurate and faster genomic insights.

What Factors Are Driving the Growth in the Short-Read Sequencing Market?

The growth in the Short-Read Sequencing market is driven by several factors, including the increasing demand for genomic research in fields like oncology, infectious diseases, and personalized medicine. The growing focus on precision medicine, which relies heavily on genetic insights for tailored treatment, has accelerated the adoption of short-read sequencing in clinical settings. Advancements in sequencing technology, such as higher throughput and reduced costs, have made sequencing more accessible to a broader range of applications. The expanding use of bioinformatics tools and cloud-based data analysis has improved the efficiency of sequencing workflows, supporting broader adoption. Additionally, government funding for genomics research and the development of new diagnostic solutions have contributed to the growth of the short-read sequencing market.

Select Competitors (Total 32 Featured) -

• BGI Genomics Co Ltd.
• CD Genomics
• Element Biosciences
• Illumina, Inc.
• Integra Biosciences AG
• MedGenome, Inc.
• Oxford Nanopore Technologies, Ltd.
• Pacific Biosciences of California, Inc.
• seqWell
• Thermo Fisher Scientific, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.